Blood coagulation cascade protein

**Blood coagulation cascade proteins** comprise a group of mostly liver-derived plasma enzymes and cofactors (commonly called clotting or coagulation factors) responsible for the tightly regulated process of hemostasis. These proteins interact in a well-characterized enzymatic cascade that includes the intrinsic, extrinsic, and common pathways, ultimately producing a fibrin clot to prevent blood loss after vascular injury[3][5]. This cascade involves both procoagulant and anticoagulant pathways, is essential for wound healing, and its dysregulation is central to the pathology of thrombotic and bleeding disorders. Therapeutically, components like Factor II (thrombin) and Factor XI have been identified as promising targets for safer and more effective anticoagulant drug development, as their inhibition can reduce risk for conditions such as venous thromboembolism and cardioembolic stroke without substantially increasing bleeding risk[1][2]. "Blood coagulation cascade proteins" is a collective rather than a specific molecule; for targeted purposes, specific individual coagulation factors (e.g., Factor XI, Factor II) are considered canonical therapeutic targets[1][2][3]. **Note on correctness:** "Blood coagulation cascade proteins" is too broad and non-specific for a canonical therapeutic target name. The therapeutically relevant units are individual clotting factors (e.g., Factor XI, Factor II/prothrombin), each with its own specific abbreviation and classification. Therefore, this entry is marked as "is_incorrect: true" for the purposes of canonical therapeutic target mapping[1][2][3].

Other names

Coagulation factorClotting factorCoagulation cascade protein

Inhibition of enzyme activity within the cascade (e.g., factor IIa [thrombin] inhibitors, factor Xa inhibitors, factor XIa inhibitors), Vitamin K antagonism